# Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination

> **NCT04868877** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Merus B.V.** · enrollment: 194 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer Metastatic
- Gastric Cancer
- Esophageal Squamous Cell Carcinoma
- Head and Neck Squamous Cell Carcinoma
- Colorectal Cancer

## Interventions

- **DRUG:** MCLA-129
- **DRUG:** Osimertinib
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT04868877
- **Lead sponsor:** Merus B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-04-28
- **Primary completion:** 2026-03
- **Final completion:** 2027-03
- **Target enrollment:** 194 (ACTUAL)
- **Last updated:** 2026-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04868877

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04868877, "Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04868877. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*